Media Release related to Stock Split and Bonus Issue
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals Ltd has informed the BSE that its Board of Directors will meet on 22 August 2025 to consider two shareholder-friendly corporate actions: a sub-division (stock split) of equity shares in the ratio of 1:10, and a bonus issue of up to 1:1 (one bonus share for every one share held). Both proposals are subject to Board approval, shareholder consent, and regulatory clearances. If approved in sequence, a shareholder holding 1 share today would end up with up to 20 shares, without any change in their proportional ownership or total market value. The trading window for insiders is currently closed and will reopen 48 hours after the Board outcome is disclosed. The company describes itself as a debt-free, India-based healthcare firm focused on fee-based pharmaceutical procurement and export sourcing.
If approved, the stock split would lower the per-share price and make shares more accessible to retail investors, potentially boosting trading liquidity, while the bonus issue rewards existing shareholders without any cash outflow. Neither action changes the company's market capitalisation or a shareholder's effective stake, so this is largely a positive sentiment-driven event that may attract short-term price attention around the 22 August Board meeting.